BIFIDO Co., Ltd. (KOSDAQ:238200)
South Korea · Delayed Price · Currency is KRW 2,735.00
-10.00 (-0.36%)
At close: Sep 11, 2026
BIFIDO Revenue
BIFIDO had revenue of 3.60B KRW in the quarter ending June 30, 2026, a decrease of -41.88%. This brings the company's revenue in the last twelve months to 14.63B, down -15.44% year-over-year. In the year 2025, BIFIDO had annual revenue of 19.68B with 59.34% growth.
Revenue (ttm)
14.63B
Revenue Growth
-15.44%
P/S Ratio
1.53
Revenue / Employee
176.28M
Employees
83
Market Cap
22.37B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 19.68B | 7.33B | 59.34% |
| Dec 31, 2024 | 12.35B | -6.28B | -33.72% |
| Dec 31, 2023 | 18.63B | 4.06B | 27.82% |
| Dec 31, 2022 | 14.58B | 2.46B | 20.32% |
| Dec 31, 2021 | 12.12B | -264.16M | -2.13% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Hurum | 94.89B |
| Korean Drug | 65.39B |
| ChoA Pharmaceutical Co., LTD. | 61.16B |
| WooGene B&G | 56.49B |
| CXI Healthcare Technology Group | 51.45B |
| Seoul Pharma | 51.08B |
| Union Korea Pharm | 25.45B |
| Daesung Microbiological Labs. | 25.20B |